DIA Biosimilars 2013

GNS Healthcare

GNS Healthcare joins Orion Bionetworks to develop predictive models

Monday, March 4, 2013 02:08 PM

GNS Healthcare has joined in the formation of Orion Bionetworks. This unique alliance will work to transform understanding of and accelerate the drug development process for a wide variety of diseases, beginning with multiple sclerosis (MS).

More... »

Cenduit: Now with Patient Reminders

GNS Healthcare, Dana-Farber, Mount Sinai to build computer model of multiple myeloma

Tuesday, November 13, 2012 01:57 PM

GNS Healthcare, a healthcare data analytics company, has entered into a collaboration with Dana-Farber Cancer Institute and the Mount Sinai School of Medicine to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S.

More... »

CRF Health – eCOA Forum

GNS Healthcare, Covance to enable more efficient, cost-effective drug development

Friday, September 21, 2012 02:31 PM

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

More... »

GNS constructs immuno-inflammation model with BMS trial data

Wednesday, August 17, 2011 10:17 AM

A computer model that can support virtual clinical trials in the field of immuno-inflammation is the goal of a new collaboration between Bristol-Myers Squibb (BMS) and US-based healthcare analytics company GNS Healthcare, according to PharmaTimes.

More... »

GNS, Bristol-Myers Squibb collaborate

Wednesday, August 10, 2011 12:14 PM

GNS Healthcare, a healthcare analytics company focused on enabling personalized medicine to improve human health, has entered into a collaboration with Bristol-Myers Squibb focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation. Utilizing its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform, GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms.

More... »

Biogen Idec, GNS target personalized medicine

Thursday, March 17, 2011 11:53 AM

Using a patient dataset and high-horsepower computing, researchers at Biogen Idec and analytics company GNS Healthcare have built a rheumatoid arthritis disease model that lets them run patient-specific virtual clinical trials, according to Fierce Biotech IT. This personalized-medicine stepping stone yields dynamic disease models of individualized patient outcomes.

More... »

Via Science creates predictive models to help sponsors better use complex research data

Monday, December 6, 2010 07:16 AM

New “big data” analytics company Via Science will market technology that allows drug sponsors to use the massive amount of complex data generated in research when making decisions about their drug development candidates and strategies.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs